Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals

Drug Profile

Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals

Alternative Names: Accu-Break Warfarin Potassium; Accu-Break-formatted anticoagulant

Latest Information Update: 22 Nov 2015

Price : $50

At a glance

  • Originator Accu-Break Pharmaceuticals
  • Developer Accu-Break Pharmaceuticals; Alembic
  • Class Anti-ischaemics; Anticoagulants; Coumarins
  • Mechanism of Action Vitamin K antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Thromboembolism

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Nov 2015 Warfarin - Accu-Break Pharmaceuticals/Alembic Pharmaceuticals is available for licensing in USA, World as of 19 Nov 2015. www.accubreakpharmaceuticals.com
  • 19 Nov 2015 Preregistration for Thromboembolism in USA (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top